UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
A structured five-chapter course for understanding biotech catalysts, clinical trial data, FDA decisions, valuation, dilution risk and due diligence—without signals, shortcuts or promises of profit.
English edition · Fully revised July 16, 2026
Biotech is one of the few public-market sectors where a single press release can radically change the value of a company. A pivotal trial can validate or destroy a thesis. An FDA decision can unlock a commercial asset or expose manufacturing, safety or benefit-risk problems. A financing can extend a runway while simultaneously changing the value of every existing share.
This masterclass connects those moving parts into one repeatable process. It teaches readers how to identify a catalyst, verify the date, understand the evidence, compare the result with expectations, assess the balance sheet and decide what remains uncertain. The objective is not to predict every outcome. It is to stop confusing a compelling story with a complete analysis.
Each chapter answers a different question, but they are designed to work together. Reading only the catalyst date without understanding the data, valuation and financing risk is not a complete process.
Learn how regulatory events, clinical readouts, financings, partnerships, conferences and commercial updates move expectations—and why a catalyst is not automatically bullish or bearish.
Move beyond “endpoint met.” Study trial design, patient population, controls, effect size, confidence intervals, multiplicity, safety, subgroup claims and the difference between statistical and clinical significance.
Understand NDA and BLA reviews, standard versus priority review, advisory committees, labeling, CMC and inspections, approval scenarios, Complete Response Letters and the market risk around target action dates.
Build a transparent valuation from patients, penetration, price, revenue ramp, probability of success and operating economics. Then incorporate cash, debt, milestones, royalties, share count and future dilution.
Combine clinical evidence, regulatory risk, manufacturing, governance, competition, intellectual property, financing and disclosure quality into a repeatable checklist. The final chapter also provides a rapid scan and a full deep-dive workflow.
The course uses a simple chain called the 5E model. It is not a trading signal. It is a way to expose missing work before a position is built around incomplete information.
A calendar entry tells you that an event may occur. It does not tell you whether the evidence is strong, whether the event is already anticipated, whether financing is likely before or after it, or whether the potential reward compensates for the downside. The rest of the masterclass exists to answer those questions.
Read one chapter per day. At the end of each chapter, apply its checklist to one live company without taking any action. The exercise is analysis, not execution.
Read each chapter, then spend one or two sessions checking the same topic in primary documents. This is the best format for readers building a repeatable workflow.
Return directly to the relevant chapter when a trial, PDUFA date, financing or valuation question appears. The pages are structured to work as evergreen reference guides.
Biotech information is frequently repeated, simplified and distorted as it moves from an official document to a headline and then to social media. This course treats primary documents as the starting point.
Reddit, Stocktwits and X can reveal attention, positioning and popular narratives. They cannot replace a protocol, an FDA document, a filing or a complete data table. A confident post is not a primary source.
The masterclass explains how market participants may analyze catalyst-driven biotech securities, how to verify information and how to identify uncertainty. It can support independent research and help readers ask better questions.
No chapter tells readers to buy, sell or hold a security. No framework eliminates binary risk, gaps, dilution, liquidity problems or analytical error. Personal financial circumstances, time horizon and risk capacity are outside the scope of this publication.
Yes. The course is published as free educational content on Merlintrader. Readers who find it useful can support the project by sharing it, joining the community or making a voluntary contribution through the support options available on the site.
No. RunUP Biotech refers to studying the period in which attention, expectations, liquidity and positioning may develop before a catalyst. Whether a person holds, reduces or avoids exposure is a separate risk decision. The course does not prescribe an execution strategy.
Yes. Trial readouts can move within guidance windows, regulatory target dates can be extended, conference schedules can change and companies can revise timelines. Dates should be checked repeatedly against official sources.
No. The reaction depends on the details, prior expectations, valuation, safety, competitive differentiation, financing needs and positioning. A technically positive result can disappoint if the market expected more.
Because company value and per-share value are not the same. A program can progress while an expanding share count, warrants, convertibles or new offerings alter the outcome for existing shareholders.
Begin with Chapter 1, then follow the sequence. Keep the Catalyst Calendar, Biotech Tools Hub and primary-source sites open while reading.
Chapter 1 explains how to identify, verify and classify biotech catalysts before evaluating the evidence, expectations and exposure around them.